Which diabetes drug best protects kidneys and heart?
Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study compared three types of diabetes drugs to see which one does the best job at keeping the heart and kidneys safe in people with diabetes and kidney disease.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 561 / 100
Evidence Score
The highest quality evidence. These studies systematically search, appraise, and synthesize results from multiple individual studies, providing the most reliable summary of current knowledge.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study compared three types of diabetes drugs to see which one does the best job at keeping the heart and kidneys safe in people with diabetes and kidney disease.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 561 / 100
Evidence Score
The highest quality evidence. These studies systematically search, appraise, and synthesize results from multiple individual studies, providing the most reliable summary of current knowledge.
Publication
Authors
Zhang Y, Jiang L, Wang J, Wang T, Chien C, Huang W, Fu X, Xiao Y, Fu Q, Wang S, Zhao J
Related Content
Claims (9)
GLP-1 receptor agonists lower the risk of heart and kidney complications in people with type 2 diabetes and chronic kidney disease by directly activating GLP-1 receptors, regardless of changes in body weight or use of mineralocorticoid receptor antagonists.
In patients with type 2 diabetes and chronic kidney disease, GLP-1 receptor agonists do not significantly lower the risk of kidney-related complications compared to no treatment, based on a risk ratio of 0.90 with a confidence interval that includes no effect.
In patients with type 2 diabetes and chronic kidney disease, sodium-glucose cotransporter-2 inhibitors lower the rate of hospitalization for heart failure by 40% compared to placebo, and this reduction is greater than that seen with finerenone or GLP-1 receptor agonists.
In patients with type 2 diabetes and chronic kidney disease, finerenone lowers the incidence of major adverse cardiovascular events by 12% compared to placebo, with a similar level of effectiveness as SGLT2 inhibitors and GLP-1 receptor agonists.
In patients with type 2 diabetes and chronic kidney disease, sodium-glucose cotransporter-2 inhibitors lower the risk of kidney-related complications by 33% compared to placebo, and this reduction is larger than the reduction seen with finerenone or GLP-1 receptor agonists.